CONMED Corp. Stock
CONMED Corp. Stock
A loss of -1.960% shows a downward development for CONMED Corp..
Our community is currently high on CONMED Corp. with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 53 € shows a very positive potential of 76.67% compared to the current price of 30.0 € for CONMED Corp..
Pros and Cons of CONMED Corp. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of CONMED Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| CONMED Corp. | -1.960% | -5.063% | -23.077% | -44.954% | -14.286% | -68.085% | -72.973% |
| Bio-Rad Labs Inc. A | -0.660% | 2.341% | 0.460% | 6.278% | -6.786% | -44.455% | -50.535% |
| Haemonetics Corp. | 0.820% | -5.000% | -10.182% | - | -27.883% | - | - |
| Neogen Corp. | 1.920% | 1.258% | -15.707% | 1.258% | 30.894% | - | - |
Comments
CONMED (CNMD) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for CNMD provided by MarketBeat
CONMED (NYSE:CNMD) had its price target lowered by analysts at Piper Sandler from $68.00 to $55.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat
CONMED Corporation (NYSE: CNMD) had its price target lowered by analysts at Piper Sandler from $80.00 to $68.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CNMD provided by MarketBeat